Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Núria Jordana‐Ariza"'
Autor:
Silvia García-Roman, Mónica Garzón-Ibáñez, Jordi Bertrán-Alamillo, Núria Jordana-Ariza, Ana Giménez-Capitán, Beatriz García-Peláez, Marta Vives-Usano, Jordi Codony-Servat, Erik d'Hondt, Rafael Rosell, Miguel Ángel Molina-Vila
Publikováno v:
Translational Oncology, Vol 40, Iss , Pp 101878- (2024)
Background: The EGFR pathway is involved in intrinsic and acquired resistance to a wide variety of targeted therapies in cancer. Vaccination represents an alternative to the administration of anti-EGFR monoclonal antibodies, such as cetuximab or pani
Externí odkaz:
https://doaj.org/article/fc3b1c5adf764070ae7e5f5cd5f1ee1a
Autor:
Ruth Román-Lladó, Cristina Aguado, Núria Jordana-Ariza, Jaume Roca-Arias, Sonia Rodríguez, Erika Aldeguer, Mónica Garzón-Ibañez, Beatriz García-Peláez, Marta Vives-Usano, Ana Giménez-Capitán, Andrés Aguilar, Alejandro Martinez-Bueno, María Gonzalez Cao, Florencia García-Casabal, Santiago Viteri, Clara Mayo de las Casas, Rafael Rosell, Miguel Angel Molina-Vila
Publikováno v:
Journal of Molecular Pathology, Vol 4, Iss 1, Pp 57-68 (2023)
Genetic and drug sensitivity assays on primary cultures are not only of basic but also of translational interest and could eventually aid oncologists in the selection of treatments. However, cancer cells need to be identified and differentiated from
Externí odkaz:
https://doaj.org/article/4aa6f599da1a468abb18119b19ad755f
Autor:
Nadine Reischmann, Carolin Schmelas, Miguel Ángel Molina-Vila, Núria Jordana-Ariza, Daniel Kuntze, Silvia García-Roman, Manon A. Simard, Doreen Musch, Christina Esdar, Joachim Albers, Niki Karachaliou
Publikováno v:
iScience, Vol 26, Iss 7, Pp 107006- (2023)
Summary: This study evaluates the efficacy of combining targeted therapies with MET or SHP2 inhibitors to overcome MET-mediated resistance in different NSCLC subtypes. A prevalence study was conducted for MET amplification and overexpression in sampl
Externí odkaz:
https://doaj.org/article/212794a83ace4b01a781beca9b628143
Autor:
Sergio Villatoro, Clara Mayo‐de‐las‐Casas, Núria Jordana‐Ariza, Santiago Viteri‐Ramírez, Mónica Garzón‐Ibañez, Irene Moya‐Horno, Beatriz García‐Peláez, María González‐Cao, Umberto Malapelle, Ariadna Balada‐Bel, Alejandro Martínez‐Bueno, Raquel Campos, Noemí Reguart, Margarita Majem, Remei Blanco, Ana Blasco, María J. Catalán, Xavier González, Giancarlo Troncone, Niki Karachaliou, Rafael Rosell, Miguel A. Molina‐Vila
Publikováno v:
Molecular Oncology, Vol 13, Iss 12, Pp 2633-2645 (2019)
Many advanced cases of cancer show central nervous system, pleural, or peritoneal involvement. In this study, we prospectively analyzed if cerebrospinal fluid (CSF), pleural effusion (PE), and/or ascites (ASC) can be used to detect driver mutations a
Externí odkaz:
https://doaj.org/article/768780ab545245d49c5080fab9f9fe1b
Autor:
Galatea Kallergi, Emmanouil Kontopodis, Aliki Ntzifa, Núria Jordana-Ariza, Niki Karachaliou, Evangelia Pantazaka, Haris A. Charalambous, Amanda Psyrri, Emily Tsaroucha, Ioannis Boukovinas, Anna Koumarianou, Dora Hatzidaki, Evi Lianidou, Vassilis Georgoulias, Rafael Rosell, Athanasios Kotsakis
Publikováno v:
Cancers, Vol 14, Iss 6, p 1574 (2022)
Introduction: Liquid biopsy is a useful tool for monitoring treatment outcome in solid tumors, including lung cancer. The relevance of monitoring CTCs and plasma ctDNA as predictors of clinical outcome was assessed in EGFR-mutant NSCLC patients treat
Externí odkaz:
https://doaj.org/article/1d91e608a7224985ad1d37477d9e5ce6
Autor:
Cristina Aguado, Ana Giménez-Capitán, Ruth Román, Sonia Rodríguez, Núria Jordana-Ariza, Andrés Aguilar, Carlos Cabrera-Gálvez, Carlos Rivas-Corredor, Pilar Lianes, Santiago Viteri, Irene Moya, Miguel A. Molina-Vila
Publikováno v:
Diagnostics, Vol 11, Iss 1, p 15 (2020)
The detection of ALK receptor tyrosine kinase (ALK), ROS proto-oncogen1, receptor tyrosine kinase (ROS1), ret proto-oncogen (RET), and MET proto-oncogen exon 14 skipping (METΔex14) allows for the selection of specific kinase inhibitor treatment in p
Externí odkaz:
https://doaj.org/article/0a4ea50edaa44fe884f0020201ecb8aa
Autor:
Núria Jordana-Ariza, Nadine Reischmann, Carlos Esparré, Ruth Román, Cristina Aguado-Esteban, Silvia García-Román, Christopher Stroh, Andrés Aguilar Aguilar, Rafael Rosell, Niki Karachaliou, Miguel A. Molina-Vila
Publikováno v:
Cancer Research. 82:1106-1106
Background: ALK and ROS1 fusion-positive NSCLC patients derive clinical benefit from tyrosine kinase inhibitors (TKIs) but ultimately relapse. Acquired resistance mechanisms include on-target secondary mutations or copy number gains and activation of
Autor:
Andrés Aguilar, Eric J Johnson, Chung-Ying Huang, Joseph M. Beechem, Noemi Reguart, Mónica Garzón, Beatriz Garcia, Sarah Warren, Jillian Wilhelmina Paulina Bracht, Clara Mayo-de-las-Casas, Alejandro Martinez-Bueno, Ivana-Gabriela Sullivan, Ana Giménez-Capitán, Núria Jordana-Ariza, Jay Gerlach, Cristina Teixidó, Rafael Rosell, Santiago Viteri-Ramirez, Juan José García, Miguel Angel Molina-Vila
Publikováno v:
CLINICAL CHEMISTRY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Clinical Chemistry
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Clinical Chemistry
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Background With the advent of precision oncology, liquid biopsies are quickly gaining acceptance in the clinical setting. However, in some cases, the amount of DNA isolated is insufficient for Next-Generation Sequencing (NGS) analysis. The nCounter p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d4b324a464cdc6716f91f4f2dd19d6b
https://ddd.uab.cat/record/272084
https://ddd.uab.cat/record/272084
Autor:
Miguel Angel Molina-Vila, Núria Jordana-Ariza, Santiago Viteri, Sonia Rodríguez, Ruth Román, Ana Giménez-Capitán, Andrés Aguilar, Cristina Aguado, Carlos Rivas-Corredor, Pilar Lianes, Irene Moya, Carlos Cabrera-Gálvez
Publikováno v:
Diagnostics
Volume 11
Issue 1
Diagnostics, Vol 11, Iss 15, p 15 (2021)
Volume 11
Issue 1
Diagnostics, Vol 11, Iss 15, p 15 (2021)
The detection of ALK receptor tyrosine kinase (ALK), ROS proto-oncogen1, receptor tyrosine kinase (ROS1), ret proto-oncogen (RET), and MET proto-oncogen exon 14 skipping (MET&Delta
ex14) allows for the selection of specific kinase inhibitor trea
ex14) allows for the selection of specific kinase inhibitor trea
Autor:
Niki Karachaliou, Zoi Tsourti, Bartomeu Massuti, Santiago Ponce Aix, Martin Früh, Miklos Pless, Paolo Bidoli, Núria Jordana-Ariza, Ariadna Balada-Bel, H. Roschitzki-Voser, Enriqueta Felip, Solange Peters, Mónica Garzón-Ibáñez, Roswitha Kammler, Ramon Palmero, Sinead Cuffe, Clara Mayo-de-las-Casas, Rafael Rosell, Sanjay Popat, Enric Carcereny, M.A. Molina-Vila, Oliver Gautschi, Beatriz García-Peláez, Rolf A. Stahel, Urania Dafni, Alessandra Curioni Fontecedro
Publikováno v:
Journal of Thoracic Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Universidad de Alicante (UA)
JOURNAL OF THORACIC ONCOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-IGTP: Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Institut de Recerca Germans Trias i Pujol (IGTP)
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Universidad de Alicante (UA)
JOURNAL OF THORACIC ONCOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-IGTP: Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Institut de Recerca Germans Trias i Pujol (IGTP)
Introduction: Longitudinal evaluation of mutations in blood samples was a prespecified secondary objective in the BELIEF trial of erlotinib and bevacizumab in advanced EGFR-positive NSCLC. Here, we report the testing results and explore the correlati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::994673a7e864203d23813318e7ec156a
http://hdl.handle.net/10281/260723
http://hdl.handle.net/10281/260723